| About Us |
Combining over 100 years of FDA and Industry experience, IHL Consulting Group,
Inc. is comprised of FDA consultants committed to providing a full range of consulting
services in the areas of pharmaceutical, medical device, and biologics regulatory
compliance. From the early stages of development to commercial production, our
consultants have serviced small start-up clients as well as multi-national Fortune 500
companies. Our goal is to provide you with courteous, expedient, pragmatic and
professional advice of the highest caliber - whether it is a small assignment or a
comprehensive compliance solution. With former FDA Field Investigators and industry
experts on staff, we offer a unique and blended perspective from the regulatory and
industry environments.
IHL Consulting Group, Inc. has also formed strategic alliances with other regulatory
service professionals/partners when your needs call for specialized attention.
Inc. is comprised of FDA consultants committed to providing a full range of consulting
services in the areas of pharmaceutical, medical device, and biologics regulatory
compliance. From the early stages of development to commercial production, our
consultants have serviced small start-up clients as well as multi-national Fortune 500
companies. Our goal is to provide you with courteous, expedient, pragmatic and
professional advice of the highest caliber - whether it is a small assignment or a
comprehensive compliance solution. With former FDA Field Investigators and industry
experts on staff, we offer a unique and blended perspective from the regulatory and
industry environments.
IHL Consulting Group, Inc. has also formed strategic alliances with other regulatory
service professionals/partners when your needs call for specialized attention.
Robert L. Lewis, President: Robert has been a consultant to US FDA regulated
industries since September 2000 when he founded IHL Consulting Group, Inc. During his
ten years with the US Food and Drug Administration, Robert served as an Investigator /
Drug/Pharmaceutical Specialist, Robert conducted numerous cGMP and NDA / ANDA pre-
Approval inspections at major domestic and international pharmaceutical facilities. He
was also Co-Leader of Atlanta District Drug Team, and the Assistant ANDA / NDA Pre-
Approval Program Manager. Robert now provides regulatory advice to a diverse array of
clients, including specialized consultation at the Executive and Leadership level. Robert
has been a frequent speaker at industry conferences and currently oversees all IHL
consulting operations. He holds a Bachelor of Science Degree in Applied Biology from
Georgia Tech.
Robert C. (Bob) Coleman, Senior Compliance Expert, Pharmaceuticals Bob recently
retired after 35 years with FDA, the last 13 of which he was the National Drug Expert
Investigator. As a Drug Specialist and the National Drug Expert, Bob conducted literally
hundreds of cGMP and Pre-Approval drug inspections both domestically and inter-
nationally, specializing in sterile dosage forms and aseptic processing. He has been one
of the principal instructors in fundamental FDA drug training courses for Investigators and
was instrumental in the FDA Drug Certification program, serving as Board Member for both
the Level II and Level III/Pharmaceutical Inspectorate Boards. Bob has also received
special recognition at the highest levels including the Commissioner’s Special Citation and
Outstanding Service Awards.
Karen A. Coleman, Senior Compliance Expert, Medical Devices Karen retired after 30
years with FDA, the last 15 of which she was the National Device Expert Investigator. As
a Device Specialist and as the National Device Expert, Karen has conducted key cGMP
and Pre-Market inspections involving the most complex devices and diagnostic equipment,
including sterile devices [e.g. angioplasty devices, stents, heart valves, pacemakers,
dialysis filters, urinary catheters and other latex products; blood filters, contacts, and
surgical equipment], tissue devices, and radiological equipment. She has served as a
principal FDA instructor in fundamental agency device training courses and was an
instrumental FDA representative on the Global Harmonization Task Force {GHTF - Study
Group 4 (Auditing)} which included work on major GHTF guidance documents for
Regulatory Auditing, Audit Strategy, and Regulatory Audit Reports. Karen has also
received special agency recognition at the highest levels including the Commissioner’s
Special Citations, Commendable Service Awards, and Outstanding Service Awards.
Jennifer Ahearn, Compliance Consultant. Jennifer joined IHL as a Compliance
Consultant in November of 2008. For six years prior, Jennifer was employed as a Chemist
and Investigative Analyst with the US Food and Drug Administration's Atlanta District.
During her FDA tenure, she evaluated and analyzed compliance and surveillance drug
samples from throughout the country, including those related to NDAs or ANDAs,
consumer complaints, and criminal investigations. She further served as the Acting
Quality Assurance Manager for the Southeast Regional Laboratory. As an Investigative
Analyst, Jennifer's duties included serving as lead investigator in complex inspections of
pharmaceutical firms assessing manufacturing operations along with analytical and
microbiological laboratories. She conducted numerous cGMP, NDA/ANDA Pre-Approval,
and Compliance Inspections both nationally and internationally. These inspections
included evaluation of most pharmaceutical dosage forms and included cases involving
sanctions, litigation, and Criminal Investigations. Jennifer has prepared seminars, industry
meetings, and conferences regarding regulatory compliance issues. She was also
selected to provide national training to FDA Investigators at FDA's Basic Drug School, Pre-
Approval Inspection courses, and at the Introduction to Pharmaceutical Inspections for
Analysts course. She has also assisted in the development of district and national FDA
policies and regulations. Jennifer has received letters of commendation on her investigative
work and testimony from FDA's Office of General Counsel, Department of Justice, US
Attorney's Office, and FDA's Center for Drug Evaluation and Research.
industries since September 2000 when he founded IHL Consulting Group, Inc. During his
ten years with the US Food and Drug Administration, Robert served as an Investigator /
Drug/Pharmaceutical Specialist, Robert conducted numerous cGMP and NDA / ANDA pre-
Approval inspections at major domestic and international pharmaceutical facilities. He
was also Co-Leader of Atlanta District Drug Team, and the Assistant ANDA / NDA Pre-
Approval Program Manager. Robert now provides regulatory advice to a diverse array of
clients, including specialized consultation at the Executive and Leadership level. Robert
has been a frequent speaker at industry conferences and currently oversees all IHL
consulting operations. He holds a Bachelor of Science Degree in Applied Biology from
Georgia Tech.
Robert C. (Bob) Coleman, Senior Compliance Expert, Pharmaceuticals Bob recently
retired after 35 years with FDA, the last 13 of which he was the National Drug Expert
Investigator. As a Drug Specialist and the National Drug Expert, Bob conducted literally
hundreds of cGMP and Pre-Approval drug inspections both domestically and inter-
nationally, specializing in sterile dosage forms and aseptic processing. He has been one
of the principal instructors in fundamental FDA drug training courses for Investigators and
was instrumental in the FDA Drug Certification program, serving as Board Member for both
the Level II and Level III/Pharmaceutical Inspectorate Boards. Bob has also received
special recognition at the highest levels including the Commissioner’s Special Citation and
Outstanding Service Awards.
Karen A. Coleman, Senior Compliance Expert, Medical Devices Karen retired after 30
years with FDA, the last 15 of which she was the National Device Expert Investigator. As
a Device Specialist and as the National Device Expert, Karen has conducted key cGMP
and Pre-Market inspections involving the most complex devices and diagnostic equipment,
including sterile devices [e.g. angioplasty devices, stents, heart valves, pacemakers,
dialysis filters, urinary catheters and other latex products; blood filters, contacts, and
surgical equipment], tissue devices, and radiological equipment. She has served as a
principal FDA instructor in fundamental agency device training courses and was an
instrumental FDA representative on the Global Harmonization Task Force {GHTF - Study
Group 4 (Auditing)} which included work on major GHTF guidance documents for
Regulatory Auditing, Audit Strategy, and Regulatory Audit Reports. Karen has also
received special agency recognition at the highest levels including the Commissioner’s
Special Citations, Commendable Service Awards, and Outstanding Service Awards.
Jennifer Ahearn, Compliance Consultant. Jennifer joined IHL as a Compliance
Consultant in November of 2008. For six years prior, Jennifer was employed as a Chemist
and Investigative Analyst with the US Food and Drug Administration's Atlanta District.
During her FDA tenure, she evaluated and analyzed compliance and surveillance drug
samples from throughout the country, including those related to NDAs or ANDAs,
consumer complaints, and criminal investigations. She further served as the Acting
Quality Assurance Manager for the Southeast Regional Laboratory. As an Investigative
Analyst, Jennifer's duties included serving as lead investigator in complex inspections of
pharmaceutical firms assessing manufacturing operations along with analytical and
microbiological laboratories. She conducted numerous cGMP, NDA/ANDA Pre-Approval,
and Compliance Inspections both nationally and internationally. These inspections
included evaluation of most pharmaceutical dosage forms and included cases involving
sanctions, litigation, and Criminal Investigations. Jennifer has prepared seminars, industry
meetings, and conferences regarding regulatory compliance issues. She was also
selected to provide national training to FDA Investigators at FDA's Basic Drug School, Pre-
Approval Inspection courses, and at the Introduction to Pharmaceutical Inspections for
Analysts course. She has also assisted in the development of district and national FDA
policies and regulations. Jennifer has received letters of commendation on her investigative
work and testimony from FDA's Office of General Counsel, Department of Justice, US
Attorney's Office, and FDA's Center for Drug Evaluation and Research.
IHL Consulting Group, Inc.
Strategic Solutions for FDA Compliance
Strategic Solutions for FDA Compliance
| Honest. Pragmatic. Responsive. Regulatory Advice You Can Trust. |
| Our Core Team |
USFDA Pharmaceutical, Medical Device
and Biologics Regulatory Consulting
and Biologics Regulatory Consulting
